1	Biomarkers of insulin resistance and their performance as predictors of treatment response
2	in adults with risk factors for type 2 diabetes.
3	
4	RJ Brogan ^{1,2} , O Rooyackers ³ , BE Phillips ⁴ , B Twelkmeyer ³ , LM Ross ⁵ , PJ Atherton ³ , WE
5	Kraus ⁵ , JA Timmons ^{2,6*} and IJ Gallagher ^{7*}
6	
7	Affiliations
8	
9	¹ Anaesthesia, Pain and Perioperative Medicine, Fiona Stanley Hospital, Perth, WA, Australia
10	² Augur Precision Medicine LTD, Stirling, Scotland
11	³ Division of Anesthesiology and Intensive Care, CLINTEC, Karolinska Institutet, Sweden
12	⁴ Clinical, Metabolic and Molecular Physiology Research Group, School of Medicine, University
13	of Nottingham, Derby, England
14	⁵ Duke University School of Medicine, Durham, NC, USA
15	⁶ Faculty of Medicine and Dentistry, Queen Mary University of London, London, England
16	⁷ Center for Biomedicine and Global Health, Edinburgh Napier University, Edinburgh, Scotland
17	* Senior Authors
18	
19	Key words: T2DM, Insulin resistance, biomarkers, regression, Bayesian projective prediction
20	
21	Corresponding author: robert.brogan@health.wa.gov.au
22	
23	
24	
25	

26 Abstract

27

28 Insulin Resistance (IR) is a component of the pathogenesis of type 2 diabetes mellitus (T2DM), 29 and risk factor for cardiovascular and neurodegenerative diseases. Amino acid and lipid 30 metabolomic IR diagnostics associate with future T2DM risk in epidemiological cohorts. Whether 31 these assays can accurately detect altered IR following treatment has not been established. In the 32 present study we evaluated the ability of metabolomic diagnostics to predict altered IR following 33 exercise treatment. We evaluated the performance of two distinct insulin assays and built 34 combined clinical and metabolomic IR diagnostics. These were utilised to stratify IR status in the 35 pre-intervention fasting samples in three independent cohorts (META-PREDICT (MP, n=179), 36 STRRIDE-AT/RT (S-2, n=116) and STRRIDE-PD (S-PD, n=149)). Linear and Bayesian 37 projective prediction strategies were used to evaluate biomarkers for fasting insulin and HOMA2-38 IR and change in fasting insulin with treatment. Both insulin assays accurately quantified 39 international standard insulin (R²>0.99), yet agreement for fasting insulin was less congruent 40 $(R^2=0.65)$. Only the high-sensitivity ELISA assay could identify the mean effect of treatment on fasting insulin. Clinical-metabolomic models were statistically related to fasting insulin (R² 0.33 41 42 -0.39) but had modest capacity to classify HOMA2-IR at a clinically relevant threshold. 43 Furthermore, no model predicted treatment responses in any cohort. Thus, we demonstrate that the 44 choice of insulin assay is critical when quantifying the influence of life-style on fasting insulin, 45 while none of the clinical-metabolomic biomarkers, validated in cross-sectional data, are suitable for monitoring longitudinally changes in IR status. 46

- 47
- 48
- 49

50 Introduction

51

Chronic hyperinsulinaemia, a feature of type 2 diabetes mellitus (T2DM), contributes to a cycle of 52 53 events driving further insulin resistance (IR)¹, promoting cardiovascular² and neurodegenerative 54 diseases ³. Extreme IR also represents a distinct category of T2DM ⁴. Lifestyle based treatments are effective at reducing the risk of developing T2DM. ⁵⁻⁸ Such programs, typically involving 55 exercise training, modify IR with high intra-individual variability. 9-14 Similar variability is 56 57 observed in response to drug treatment. ^{15,16} While monitoring the efficacy of treatment on glucose 58 tolerance in large cohorts is relatively straightforward ¹⁷, the same cannot be said for monitoring 59 insulin action. ^{18,19} Furthermore, the varying characteristics of commonly used insulin assays complicate comparison across studies. 20,21 There are clear clinical definitions for diagnosing 60 61 T2DM and impaired glucose tolerance (IGT) but less so for IR, possibly due to the lack of 62 widespread measurement of insulin. This is problematic because IR is distinct from glucose 63 intolerance and can precede T2DM and slowly developing age-related diseases by decades and thus there is an urgent need to enable tracking over time IR.^{22,23} 64

65

This need for cost-effective practical IR diagnostics has stimulated the development of several clinical ²⁴ and molecular prototypes, including assays relying on branched-chain amino acids (BCAA)^{25–28}, plasma lipoproteins^{29–31} and multi-protein signatures.³² The abundance of several circulating amino acid and plasma lipids have been incorporated into statistical models that predict IR in cross-sectional, prospective or retrospective analyses (i.e. predict T2DM risk).^{25–27,29–31,33} Circulating BCAA are particularly attractive as surrogates for IR because disrupted catabolism of individual BCAA have been mechanistically and causally linked to IR, cardiovascular and

73 neurodegenerative disease processes in recent years ^{13,28,34-43}. It remains unclear how well 74 abundance of BCAA in the circulation reflects the mechanistic role of BCAA within the key tissues 75 responsible for their catabolism and therefore in turn their ability to track with changes in 76 metabolic fitness.

77

78 In addition to predicting IR, it would therefore be ideal if metabolic 'risk' biomarkers could 79 reliably associate with improvements in IR following treatment, so that non-responders could be reallocated to alternative treatments. ^{14–16,44,45} There have been attempts to establish if plasma 80 81 BCAA abundance tracks treatment responses yielding conflicting conclusions, partly because existing studies have been too small to reliably explore such relationships. ^{46,47} Determinants of 82 83 insulin action also reflect a combination of distinct acute mechanisms in the hours post-exercise, and more stable long-term adaptive changes ⁴⁸ – such as increased tissue vascularisation. ⁴⁹ Such 84 85 temporal influences have not been considered when evaluating these novel biomarkers. 86 Immediately post-exercise insulin action and glucose tolerance can be impaired, while insulin 87 responses to an oral glucose tolerance test (OGTT) appear lowest 72hr following the previous exercise training session.⁵⁰ 88

89

In the present analyses we have assessments of IR within 24hr and 48-72hr after the last training session of chronic exercise training that was effective in reducing group mean HOMA2IR. The idea is that novel biomarkers should offer practical (e.g. cost, simplicity) advantages over laboratory insulin assays, and if they can be shown to predict longitudinal changes in IR, then efforts to configure low-cost standardised assay from minimally invasive sampling would be motivated. In the present multi-study analysis, we evaluated, in hundreds of individuals at-risk for

96 T2DM, the performance of established BCAA and lipid biomarkers, combined with simple to 97 measure clinical phenotypes to estimate fasting IR and predict changes in insulin following 98 supervised lifestyle interventions.^{9,12,51,52} We established that choice of insulin assay is critical for 99 capturing interactions between exercise status and fasting insulin, while plasma biomarkers of IR 100 status, from cross-sectional and prospective studies, are unable to track with treatment responses. 101 **Results** 102 103 104 Demographic, blood and metabolomic data for the three independent cohorts - STRRIDE AT/RT 105 (S-2), STRRIDE-PD (S-PD) and MP - are presented in Table 1. 106 107 *Comparison of insulin assay and metabolomics assay performance*

108 A long-standing challenge is that commercial assays for insulin show distinct specificity and 109 sensitivity profiles, with no agreement to move to a single standard assay.^{20,21} Some historical 110 insulin assays, utilised in exercise intervention studies (e.g. HERITAGE)⁵³ or included in genome-111 wide association modelling,⁵⁴ do not show molecular associations consistent with modern more 112 specific insulin assays.¹³ We produced a large-scale comparison of two typical insulin assays (the 113 immunoassay based automated analyzer (Immulite 2000) and a manual high sensitivity ELISA kit 114 (Dako, Stockholm, Sweden), run in parallel on samples obtained before and after exercise-training 115 that reduced IR.55 Both Immulite 2000 and Dako ELISA showed near perfect (>R²=0.99) 116 correlation with the international WHO standard for insulin (National Institute for Biological 117 Standards and Control, Figure S1A-B). No cross reaction with c-peptide standard was detected 118 (data not shown). When plotting insulin values from the same fasting samples, there was moderate

agreement between the two assays (R²=0.65, Figure S2). Critically, insulin measured using the high-sensitivity ELISA was able to detect a group mean reduction following exercise training, while the Immulite 2000 immune-assay could not (Figure 1). All the subsequent analyses relied on the data generated by the Dako high-sensitivity ELISA (produced in a single laboratory).

123

124 Biomarker association with fasting insulin and HOMA2-IR status

125 Predictor variables were selected based on the literature summarised above, and availability in all 126 three cohorts. Linear regression was performed to explore individual relationships between fasting 127 insulin and the selected clinical and metabolomic biomarkers (Figure 2; full results in Table S1). 128 In MP, all pre-selected variables other than age (p=0.09) reached statistical significance for 129 association with fasting insulin (age is a reliable covariate but the age-range in MP was limited). 130 In S-2 \log_{10} BMI (p<0.001), fasting glucose (p<0.001), HDL (p=0.007), TAG (p<0.001) and amino 131 acids (isoleucine (ILE) p=0.0005, leucine (LEU) p=0.006, valine (VAL) p<0.001, alanine (ALA) 132 p=0.0027) were linearly associated with fasting insulin. Similar levels of associations were 133 observed in the S-PD cohort, except for ALA (p=0.068). For multi-variable predictors of fasting 134 insulin (or HOMA2-IR) and predictors of treatment responses, variables which showed a 135 statistically significant association in one or more of the cohorts were considered (as each was 136 supported with published evidence for having an association in cross-sectional cohorts).

137

As each study used some distinct metabolomic methods (see Methods) we performed multivariable
linear regression and logistic regression with K-fold cross validation (k=10) separately in MP, S2 and S-PD cohorts. Four models were considered; a baseline model (age, BMI and gender), a
BCAA model (age, BMI, gender and sum of BCAA), a lipid model (age, BMI, gender, HDL, LDL

142 and TAG) and finally, a combined model (age, BMI, gender, BCAA, HDL, LDL and TAG). The 143 combined model estimated fasting insulin ($\mathbb{R}^2 \ 0.33 - 0.39$), with the results in agreement with 144 previous observations (Table 2). Fasting glucose was excluded when predicting IR status. For IR 145 ROC analysis, insulin sensitive (IS, HOMA2-IR <1.3) and insulin resistant (IR, HOMA2-IR \ge 1.3) 146 was defined based on results from a large population study (n=95,540) where HOMA2-IR ≥ 1.3 147 was associated with an increased risk for the development of T2DM over a median of 4.7v (hazard 148 ratio of 3.2 (95% CI 1.9-5.3)). ⁵⁶ The four models were assessed in each cohort for their ability to 149 classify IS vs IR (Figure 3). The baseline model had no discriminatory performance in S-2, so the 150 metabolomics variables improved that model substantially, however metabolomics did not add 151 further to the clinical model ROC performance in MP or S-PD, and the best models had a modest 152 Cohens Kappa (Table S2). This illustrates that even though BCAA and lipid models statistically 153 associate with IR status, they do not contribute to a clinically useful model.

154

155 Biomarker based prediction of IR status in response to lifestyle intervention.

156 We established that each biomarker statistically associated with fasting insulin in each study 157 (Table S1) and as reported by others. Finally, we examined the utility of these biomarkers for 158 predicting exercise treatment related insulin responses in IR. For this analysis we were able to 159 include changes in fasting glucose (easy and inexpensive to measure) as we did not rely on the 160 HOMA model. Figure 4 displays the univariable linear relationships of changes in clinical and 161 metabolomic biomarkers with changes in fasting insulin as measured with the high sensitivity 162 ELISA over an exercise intervention in all three cohorts (Figure S3 provides the correlation 163 coefficients (including for individual amino acids). To examine the classification utility of 164 individual and combinations of biomarkers we built Bayesian linear models, independently for

165 each cohort, modelling change in fasting insulin after each intervention. The models included age 166 and changes over the intervention in individual BCAA, fasting glucose, BMI, lipids, systolic blood 167 pressure and alanine. The full models ("reference" models) were considered as the optimum solution to the prediction task.⁵⁷ The posterior predictive distributions showed the models 168 169 performed well and were able to predict data like that of the observed data (Fig 4A-C). Using 170 projective prediction, we found that the biomarkers did not, however, improve predictive 171 performance over a null model i.e. the intercept term (Figure 4D-F).⁵⁸ Thus, change in biomarkers 172 (alone or additively combined) could not predict change in fasting insulin following an exercise 173 intervention.

174

175 **Discussion**

176 Development of a cost-effective diagnostic for insulin sensitivity would help better understand the 177 aetiology of T2DM and aligning clinical practice with the key recommendations of the International Diabetes Federation, namely early detection and prevention of pre-diabetes.⁵⁹ 178 179 Hyperinsulinaemia drives altered insulin receptor expression potentially leading to further IR.¹ IR in turn contributes to cardiovascular disease² and dementia risk.³ Insulin is not, however, routinely 180 181 measured in the clinic and thus crucial information regarding the temporal nature of IR is lacking. 182 Previous work has identified several potential biomarkers for IR in cross-sectional and prospective settings. ^{25–27,29–31,33} The present study extends this body of work to evaluate these IR biomarkers 183 184 in the context of their ability to accurately classify changes in fasting insulin in response to exercise 185 (MP and S2) or lifestyle (S-PD) based treatment for individuals with multiple risk-factors for 186 T2DM.

188 Importance of the insulin assay

189 To our knowledge we are the first to demonstrate the importance of insulin assay choice on 190 detecting changes in fasting insulin in large scale treatment studies. The MP cohort represents a typical group of sedentary middle-aged individuals with multiple risk factors for T2DM.¹² We note 191 192 that the Immulite 2000 immunoassay was unable to detect exercise induced improvements in 193 fasting insulin, while concurrent measurements using a high sensitivity ELISA assay did. Notably 194 neither assay demonstrated any cross-reactivity with c-peptide and they both performed well in a 195 standard curve analysis. The American Diabetes Association attempted to reach a consensus on 196 standardizing the measurement of insulin.^{20,21} Our analysis indicates that if environmental 197 influences or treatment effects on fasting insulin levels are to be captured, a high-sensitivity ELISA 198 assay should be utilised. We have previously reported that some older insulin assays, with undocumented specificity (e.g. HERITAGE),⁶⁰ were unsuitable for genomic association 199 200 analysis.¹³ Indeed, it is plausible that the use of insulin assays insensitive to variations across the 201 'normal' range of fasting insulin, or with cross-reactivity for C-peptide, have undermined genomewide association modelling of fasting insulin.⁶¹ While suboptimal insulin assays will not be 202 203 voluntarily retired by manufacturers, it would seem sensible that the research community adopt 204 the use of high-sensitivity assays for studies of fasting insulin in all situations (other than extreme hyperinsulinaemia)^{20,21} especially when subtle gene-environment interactions are of interest to 205 206 study.

207

208 *Metabolomic components of the IR biomarker models*

There is a well-established positive correlation between individual circulating BCAA and greater IR ^{25–27} and pathways that control BCAA catabolism have gained interest as possible targets for

reversing IR.^{28,62,63} Furthermore, BCAA have been combined with clinical parameters to 211 reportedly increase the performance of models that predict both IR and risk of T2DM.^{29,31,33} We 212 213 previously identified, using four independent cohorts, a transcriptional signature including BCAA 214 catabolism pathway genes, that related to IR after adjustment for age, VO2max and BMI (n=564). 215 We also found that in response to four independent lifestyle interventions (n=196), expression of 216 16 genes in human skeletal muscle changed in proportion to improvements in insulin sensitivity, 217 with 25% of those related to BCAA metabolism.¹³ While this makes sense, as by mass, skeletal muscle has the largest capacity for BCAA catabolism in humans ⁶⁴ it does not provide evidence 218 219 that circulating levels of BCAA's will dynamically reflect tissue responses to insulin. In fact, 220 insulin mediated BCAA clearance may also rely on other organs including the liver.⁶⁵

221

222 In a recent study, Lee *et al* claimed that baseline plasma BCAA levels related to change in glucose 223 infusion rate during a hyperinsulinaemic-euglycaemic clamp (a measure of insulin sensitivity and 224 liver fat content ⁴⁷). This was despite no change in total plasma BCAA levels and an increase in 225 muscle BCAA catabolism pathway gene expression. We also found no change in group mean 226 blood BCAA abundance with any exercise training protocol (Table 1), which might be 227 understandable as only ~40% of subjects demonstrate a numerical improvement in HOMA2-IR 228 and some demonstrate an increase in IR.^{12,13} Nevertheless we did not find that changes in combined 229 plasma BCAA were able to predict changes in IR status. This observation is consistent with earlier 230 modelling approaches applied to the STRRIDE cohorts, where the combination of BCAA and lipid-based IR biomarkers could not predict changes in a measure of insulin sensitivity.¹⁷ Various 231 232 other combinations of BCAA and protein metabolites have been considered as IR models and while some shared variance has been observed,⁶⁶ these are most likely attributable to random 233

differences in small cohorts. Using energy restriction to modify IR, we recently reported that group
mean differences in plasma BCAA abundance were also unchanged, despite group mean
improvements in IR. ⁶⁶ All of these observations contrast with a previous study, relying on a sample
size a 10th of the present work, where changes in plasma BCAA abundance did track with improved
IR status.⁴⁶

239

240 We attempted several modelling strategies, including several distinct clinical and metabolomic 241 variables, and modelled both fasting insulin and HOMA2-IR values to ensure our negative conclusions were rigorous. We used Bayesian modelling and projective prediction ^{67,68} to establish 242 243 a sparse model that retained the ability to provide useful predictions of circulating insulin changes. 244 Projective prediction uses the predictions from the reference (full) model to identify a subset of 245 variables with predictive ability as close as possible to that of the full model. We were unable to 246 identify any set of variables useful for predicting change in circulating insulin after lifestyle 247 intervention using this strategy. Conventional regression modelling, against changes in HOMA2-248 IR also failed to identify a useful model. We can conclude that the present clinical-metabolic 249 measures are not useful for classifying a HOMA2-IR threshold value indicative of 3-fold elevated 250 risk of T2DM over 5 years, nor track altered fasting insulin with life-style interventions. This is 251 even though our ELISA-based insulin values were strongly associated with causal molecular 252 drivers of T2DM and insulin signalling in tissue samples.¹³

253

254 *Clinical evaluation of IR biomarker models*

Diagnosing IR is challenging not least because defining IR remains controversial. The gold
 standard method is commonly described as the 'clamp' technique or intravenous glucose tolerance

test.^{19,69} However, substantial resources are required for this such that it is rarely used for diagnosis 257 258 and by their nature both can be supraphysiological (re levels of insulin). Alternative IR indices 259 exist and include the homeostatic model assessment (HOMA and HOMA2^{70,71}, Matsuda index⁷² 260 and the disposition index (DI).⁷³ These are not used in clinical practice, largely due to a lack of 261 routine measurement of insulin. Although several epidemiological studies use HOMA and 262 HOMA2 for modelling IR, there is limited basis for defining a clinical cut off value. Several studies 263 unwisely use a percentile cut off identified within their individual cohort, and then apply ROC 264 curve analysis to determine the threshold for a diagnosis of IR and then relate this to relative risk 265 for relevant clinical outcomes e.g. progression to T2DM or cardiovascular disease. As a result, the 266 HOMA IR threshold used across studies, to define 'at risk', has varied from 1.8 to 3.9 depending on the population studied and methods used.¹⁸ This represents a form of model overfitting. 267

268

269 It was estimated that a HOMA2-IR more than 1.3 represented a hazard ratio of >3.2 for developing 270 T2DM over ~5 years in 95,450 subjects.⁷⁴ This analysis is the largest study to date linking a 271 particular HOMA2-IR value to incipient diabetes and we used this cutoff in the present study. 272 Interestingly, in exploratory analysis, 83% of those with the most severe IR (HOMA2-IR \geq 2.4) 273 were not classified as metabolically compromised when using fasting glucose or their 2-hourglucose OGTT data.¹² The current reliance on glucose-centric risk assessment also limits our 274 275 ability to identify and hence intervene in those people with the "least effective" response to insulin 276 (defined as the totality of all of insulin's key physiology). Nevertheless, all the surrogate variables 277 investigated in the present study have limited ability to *diagnose* IR in a cross-sectional setting, 278 and no ability to track changes in IR with life-style treatment.

279 In summary, we evaluated multiple predictive models for IR, including models incorporating well 280 validated cholesterol species and BCAA. These models failed to forecast change in IR status 281 following supervised lifestyle modification. A limitation of our study is the limited metabolomic 282 variables gathered across cohorts (although this would mainly impact on the identification of novel 283 metabolites to consider). Nevertheless, any new blood based metabolic disease biomarkers 284 reported to track improvements in insulin sensitivity across multiple independent cohorts would 285 require substantial independent clinical studies to validate beyond the level of the models evaluated 286 in the present study.

287

288

289 Materials and Methods

290

291 Clinical Cohorts

292 The MP cohort consisted of 189 active participants, recruited as previously described from five 293 geographical regions across Europe.¹² All clinical methods relied on cross-site standard operating 294 procedures (SOPs), while insulin and metabolomic measures were performed in a single central 295 laboratory. All participants were classified as sedentary (<600 metabolic equivalents (METs) 296 min·wk⁻¹) using a modified International Physical Activity Questionnaire,⁷⁵ and had a fasting 297 blood glucose level consistent with World Health Organisation (WHO) criteria for impaired 298 glucose tolerance (5.5 < IGT <7.0 mmol·l⁻¹), and/or a BMI >27 kg·m⁻². Participants were excluded 299 if they had evidence of active cardiovascular, cerebrovascular, respiratory, gastrointestinal or renal 300 disease or had a history of malignancy, coagulation dysfunction, musculoskeletal or neurological 301 disorders, recent steroid or hormone replacement therapy, or any condition requiring long-term

302 drug prescriptions. Exercise training was supervised and consisted of three high intensity cycling 303 sessions per week for 6 weeks as previously described.¹² Prior to the baseline assessments, 304 participants were instructed to refrain from exercise for three days. Supine blood pressure (Omron 305 M2, Omron Healthcare, Kyoto, Japan) and resting heart rate (RHR) were determined as the 306 average of three consecutive measurements. Blood glucose (from a dorsal hand vein) was analysed 307 before and during an (OGTT) using a YSI 2300 STAT Plus glucose analyser (Yellow Springs Inc. 308 Ohio, USA). Blood was collected in lithium heparin spray-coated vacutainers (Becton Dickinson, 309 New Jersey, USA) for analysis of insulin. The MP trial registration code is NCT01920659. The 310 STRRIDE cohorts were composed of sedentary middle-aged individuals at risk of developing 311 cardio-metabolic disease. 9,51,52 Following baseline assessments, each subject was randomized to 312 one of a variety of exercise training programs for six to eight months with or without a modified 313 diet.^{9,51,52} Pre and post clinical and physiological assessments and outcomes were as previously reported.9,51,52 314

315

316 Plasma sample insulin analysis

317 The samples from MP and the STRIDDE studies were analysed using high sensitivity insulin 318 ELISA (Dako A/S, Sweden). Two levels of QC solutions were run for insulin. Coefficients of 319 variation (CV) were acceptable; 4.68-8.03 % on both levels. As we were also using the 320 automated analyser (Immulite 2000) for analyses of all OGTT time points for insulin and c-321 peptide from the MP study, we also assessed available fasting sample profiles using this lower sensitivity immune-assay. To assure comparability of the results, we independently checked the 322 323 assay performance for cross detection of insulin and C-peptide. The WHO standard for insulin 324 and C-peptide were obtained from NIBSC (The National Institute for Biological Standards and

325	Control). A dilution series for both analytes was prepared and run on Dako ELISA and Immulite
326	2000. The diluted WHO insulin standards were subjected to the same procedure as the samples.
327	The results for both Immulite 2000 and Dako ELISA showed an acceptable correlation of
328	expected versus measured concentration with $R^2 = 0.9995$ and $R^2 = 0.9923$ for Immulite 2000
329	and Dako ELISA, respectively. The results are presented in Figure S1. No cross reaction
330	between insulin and c-peptide were detected. The two assays were in broad agreement over the
331	large concentration range of insulin used in this standard assay evaluation protocol Figure S2.

332

333 Plasma sample metabolomic analysis

334 Metabolomic analyses for MP has not been previously published (other than fasting glucose and 335 insulin). All samples were randomized for sample preparation and analyses resulting in an equal 336 distribution of all centres and possible responders and non-responders. We used hierarchical 337 clustering of metabolomic variables to highlight that there was no systematic centre specific bias 338 (Figure S4). All samples were taken after an overnight fast as arterialized venous blood and run 339 in duplicate. Results within $\pm 20\%$ CV were accepted unless otherwise stated; if this limit was not 340 met the sample was rerun. Quality controls (QC) were run for all analyses and with each batch of 341 sample preparation to ensure stable performance of the analysis procedure. QC for all analyses 342 included in house controls made from pooled EDTA plasma from healthy controls originating 343 from a previous study. The following methods were used for each metabolite. Sample analysis 344 used a Konelab 20XTi photospectrometer (Thermo Fisher Scientific, Thermo Electron Oy, Vantaa 345 Finland) for high density lipoprotein HDL cholesterol, LDL cholesterol and triacylglycerides 346 (TAG). Amino acids were analyzed using HPLC 2695 (Waters, Watford, UK) with online 347 derivatization and a fluorescence detector 474 (Waters, Watford, UK) using a method described

348 previously.^{76,77} Fatty acids were analyzed using ultra-high performance liquid chromatography 349 (Ultimate 3000 UHPLC, Thermo Fisher Scientific, Germering, Germany) coupled to a TSQ 350 Vantage with electrospray ionization (ESI) and triple quadrupole mass spectrometer (MS/MS) 351 (Thermo Fisher Scientific, San Jose, CS, USA). For the blood obtained from the STRRIDE 352 cohorts' samples were analysed for plasma glucose concentration at the research site (Duke 353 University, USA) using a Beckman–Coulter DxC600 clinical analyser (Brea, CA, United States). 354 Insulin was analyzed (in the Stockholm lab) using the high sensitivity insulin ELISA assay (Dako 355 Denmark A/S, Glostrup, Denmark); and fasted plasma samples were analysed on 400 MHz nuclear 356 magnetic resonance profilers at LipoScience, now LabCorp (Morrisville, NC, United States), as 357 previously described 78 . The lipoprotein parameters and the BCAA were identified by 358 retrospectively analysing digitally stored spectra using the newly developed NMR-based 359 lipoprotein LP4 algorithm, which correlate with mass spectrometry methods.⁷⁹

360

361 As distinct methodologies were utilised for the metabolomic analyses between MP and STRRIDE 362 cohorts we explore the compatibility of the common metabolomic data used in our diagnostic 363 models. For S-2 and S-PD, two methodologies were utilised for lipid related metabolomics and 364 Bland-Altman analysis was performed to assess measurement agreement between HDL and TAG 365 with NMR versus mass spectroscopy (Figure S5-8). There was good linear agreement between methods for HDL (S-2 r^2 0.96, p<0.001; S-PD r^2 0.89, p<0.001) and TAG (S-2 r^2 0.99, p<0.001; 366 367 S-PD r^2 0.95, p<0.001). Bland-Altman analysis revealed a mean measurement error of -0.06 368 mmol/L for HDL (S-2 Figure 5B, S-PD Figure S7B) and +0.04mmol/L (S-2 Figure 6B, S-PD 369 Figure S8B) for TAG with 95% of observations within 1.96 standard deviation of mean. Work by 370 Wolak-Dinsmore *et al* demonstrated that NMR overestimates VAL and LEU by $\geq 25\%$ (mean

value) and underestimates ILE by 10-15% (mean value) and while MS was used in MP, S-2 and
 S-PD relied on NMR for BCAA quantification. Based on these known systematic differences,⁷⁹
 modelling was performed independently in each cohort using cross-validation methods.

374

375 Statistical Modelling

376 Raw data from the clinical chemistry analyses was analysed with GraphPad Prism 5 (Software 377 MacKiev, 2007, version 5.01) and more advanced analysis was accomplished using STATISTICA 378 10 (StatSoft Inc., 2011, version 10.0.228.2). All subsequent analysis was performed in R version 379 4.1.1 and 4.3.2. We utilised conventional and Bayesian strategies to model data in the present 380 work. Potentially predictive variables were selected based on known associations with IR and 381 T2DM. Linear regression modelling was applied to investigate associations between dependent 382 and independent variables. Briefly, after reducing each dataset to complete cases common 383 variables were identified across all three cohorts. The criterion for considering a clinically useful 384 variable was pragmatic – it had to be something that could be measured cheaply and reliably in a 385 primary care setting. Laboratory measures like maximal aerobic capacity related to IR status in 386 some but not all cohorts but was not considered because of the time and cost required to measure 387 it accurately. Several variables were selected based on these ease/low-cost criteria; some variables 388 were dropped because of high collinearity (e.g. systolic blood pressure was retained in favour of 389 diastolic blood pressure and mean arterial pressure in the Bayesian analysis). We removed 390 participants with obesity class III (BMI >40kg/m²) for the Bayesian analysis and all continuous 391 variables were normalised. The latter steps were carried out using the tidymodels R package 392 (10.32614/CRAN.package.tidymodels) and applied consistently across all datasets. Collinearity 393 between variables was checked for each dataset separately (Figure S3). Apart from BCAA in the

MP dataset there were no pairwise correlations with an absolute value >0.5. Linear models were built with student-t priors on both the intercept and slope coefficient terms (df=3, mean=0 and scale=4). These were mildly informative on the scale of the normalised data. Details are in the supplementary material.

398

We built Bayesian multivariable linear models using the brms package to predict change in circulating insulin using relevant clinical variables, circulating BCAA levels and selective lipids.⁸⁰ These full models were considered reference models. We then used projective prediction to identify a subset of variables with predictive performance as close as possible to that of the reference model.⁵⁸ Briefly projective prediction first generates a solution path - the variable ranking - for each sub model examined. Next a leave-one-out cross-validation process determines the predictive performance of each sub model along the predictor ranking.

406

407 Funding

The clinical data utilised in this study was funded by multiple sources: European Union Seventh
Framework Programme (META-PREDICT, HEALTH-F2-2012-277936); STRRIDE II
(NCT00275145) by NHLBI grant HL-057354 and STRRIDE-PD (NCT00962962) by NIDDK
DK-081559 and R01DK081559. The data modelling was supported by Augur Precision Medicine
LTD.

413

414 **Competing interests**

415 None declared. JT is a major shareholder in APM, however there is no commercial link between

416 APM and the present study. There are no other financial conflicts of interest to disclose.

1	1	7
4	T	1

418 **Contributions**

- 419 RJB, JAT, OR and IJG conceptualized aims and designed the analysis strategy. All authors
- 420 contributed to the project design, data collection and/or pre-processing. RJB and IJG performed
- 421 data analysis and JAT contributed to interpretation. JAT and RJB wrote the first draft and JAT,
- 422 RJB and IJG produced a full manuscript that all authors contributed to and have read and approved
- 423 the final manuscript. JT wrote the HEALTH-F2-2012-277936 grant application.
- 424

425 Data and code availability

426 Some or all datasets generated during and/or analysed during the current study are not publicly

427 available but are available from the corresponding author on reasonable request. Data and the

428 analysis script can be found at **10.5281/zenodo.13819578**.

429

430 References

- Cen HH, Hussein B, Botezelli JD, et al. Human and mouse muscle transcriptomic analyses
 identify insulin receptor mRNA downregulation in hyperinsulinemia-associated insulin resistance.
 FASEB Journal. 2022;36(1). doi:10.1096/fj.202100497RR
- 434 2. Wamil M, Coleman RL, Adler AI, McMurray JJV, Holman RR. Increased Risk of Incident Heart
 435 Failure and Death Is Associated With Insulin Resistance in People With Newly Diagnosed Type 2
 436 Diabetes: UKPDS 89. *Diabetes Care*. 2021;44(8):1877-1884. doi:10.2337/DC21-0429
- 437 3. Folch J, Olloquequi J, Ettcheto M, et al. The Involvement of Peripheral and Brain Insulin
 438 Resistance in Late Onset Alzheimer's Dementia. *Front Aging Neurosci.* 2019;11(September):1-16.
 439 doi:10.3389/fnagi.2019.00236
- 440 4. Dennis JM, Shields BM, Henley WE, Jones AG, Hattersley AT. Disease progression and
 441 treatment response in data-driven subgroups of type 2 diabetes compared with models based on
 442 simple clinical features: an analysis using clinical trial data. *Lancet Diabetes Endocrinol.*443 2019;7(6):442-451. doi:10.1016/S2213-8587(19)30087-7
- Knowler WC, Fowler SE, Hamman RF, et al. 10-year follow-up of diabetes incidence and weight
 loss in the Diabetes Prevention Program Outcomes Study. *Lancet*. 2009;374(9702):1677-1686.

- Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. *New England Journal of Medicine*. 2013;369(2):145-154.
 doi:10.1056/NEJMoa1212914
- 449 7. Uusitupa M, Peltonen M, Lindström J, et al. Ten-year mortality and cardiovascular morbidity in
 450 the Finnish Diabetes Prevention Study Secondary analysis of the randomized trial. *PLoS One*.
 451 2009;4(5):1-8. doi:10.1371/journal.pone.0005656
- 452 8. Hivert MF, Christophi CA, Franks PW, et al. Lifestyle and metformin ameliorate insulin
 453 sensitivity independently of the genetic burden of established insulin resistance variants in
 454 diabetes prevention program participants. *Diabetes*. 2016;65(2):520-526. doi:10.2337/db15-0950
- 455 9. Ross LM, Slentz CA, Kraus WE. Evaluating Individual Level Responses to Exercise for Health
 456 Outcomes in Overweight or Obese Adults. *Front Physiol*. 2019;10. doi:10.3389/fphys.2019.01401
- Huffman KM, Slentz CA, Bateman LA, et al. Exercise-induced changes in metabolic
 intermediates, hormones, and inflammatory markers associated with improvements in insulin
 sensitivity. *Diabetes Care*. 2011;34(1):174-176. doi:10.2337/dc10-0709
- 460 11. AbouAssi H, Slentz C a, Mikus CR, et al. The Effects of Aerobic, Resistance and Combination
 461 Training on Insulin Sensitivity and secretion in Overweight Adults from STRRIDE AT/RT: A
 462 Randomized Trial. *J Appl Physiol (1985)*. 2015;118(919):jap.00509.2014.
 463 doi:10.1152/japplphysiol.00509.2014
- Phillips BE, Kelly BM, Lilja M, et al. A practical and time-efficient high-intensity interval training
 program modifies cardio-metabolic risk factors in adults with risk factors for type II diabetes. *Front Endocrinol (Lausanne)*. 2017;8(SEP):1-11. doi:10.3389/fendo.2017.00229
- Timmons JA, Atherton PJ, Larsson O, et al. A coding and non-coding transcriptomic perspective
 on the genomics of human metabolic disease. *Nucleic Acids Res.* 2018;46(15):7772-7792.
 doi:10.1093/nar/gky570
- 470 14. Álvarez C, Ramírez-Campillo R, Ramírez-Vélez R, Izquierdo M. Effects and prevalence of 471 nonresponders after 12 weeks of high-intensity interval or resistance training in women with 472 insulin resistance: a randomized trial. *J Appl Physiol*. 2017;122:985-996.
 473 doi:10.1152/japplphysiol.01037.2016.-Our
- 474 15. Sears DD, Hsiao G, Hsiao A, et al. Mechanisms of human insulin resistance and
 475 thiazolidinedione-mediated insulin sensitization. *Proc Natl Acad Sci U S A*. 2009;106(44):18745476 18750. doi:10.1073/pnas.0903032106
- 477 16. Ustinova M, Ansone L, Silamikelis I, et al. Whole-blood transcriptome profiling reveals signatures
 478 of metformin and its therapeutic response. *PLoS One*. 2020;15(8 August):1-17.
 479 doi:10.1371/journal.pone.0237400
- 480 17. Ross LM, Slentz CA, Zidek AM, et al. Effects of Amount, Intensity, and Mode of Exercise
 481 Training on Insulin Resistance and Type 2 Diabetes Risk in the STRRIDE Randomized Trials.
 482 *Front Physiol.* 2021;12(February):1-10. doi:10.3389/fphys.2021.626142
- Tang Q, Li X, Song P, Xu L. Optimal cut-off values for the homeostasis model assessment of
 insulin resistance (HOMA-IR) and pre-diabetes screening: Developments in research and
 prospects for the future. *Drug Discov Ther.* 2015;9(6):380-385. doi:10.5582/DDT.2015.01207
- 486 19. Ferrannini E, Mari A. How to measure insulin sensitivity. *J Hypertens*. 1998;16(7):895-906.
 487 doi:10.1097/00004872-199816070-00001

- 488 20. Manley SE, Stratton IM, Clark PM, Luzio SD. Comparison of II human insulin assays:
 489 Implications for clinical investigation and research. *Clin Chem.* 2007;53(5):922-932.
 490 doi:10.1373/clinchem.2006.077784
- 491 21. Miller WG, Thienpont LM, Van Uytfanghe K, et al. Toward standardization of insulin
 492 immunoassays. *Clin Chem.* 2009;55(5):1011-1018. doi:10.1373/clinchem.2008.118380
- Thambisetty M, Metter EJ, Yang A, et al. Glucose intolerance, insulin resistance, and pathological
 features of Alzheimer disease in the Baltimore Longitudinal Study of Aging. *JAMA Neurol.*2013;70(9):1167-1172. doi:10.1001/jamaneurol.2013.284
- 496 23. Rodríguez-Mañas L, Angulo J, Carnicero JA, El Assar M, García-García FJ, Sinclair AJ. Dual
 497 effects of insulin resistance on mortality and function in non-diabetic older adults: findings from
 498 the Toledo Study of Healthy Aging. *Geroscience*. 2022;44(2):1095-1108. doi:10.1007/s11357499 021-00384-4
- S00 24. Clausen JO, Borch-Johnsen K, Ibsen H, et al. Insulin sensitivity index, acute insulin response, and glucose effectiveness in a population-based sample of 380 young healthy Caucasians: Analysis of the impact of gender, body fat, physical fitness, and life-style factors. *Journal of Clinical Investigation*. 1996;98(5):1195-1209. doi:10.1172/JCI118903
- 504 25. Zheng Y, Ceglarek U, Huang T, et al. Weight-loss diets and 2-y changes in circulating amino
 505 acids in 2 randomized intervention trials. *American Journal of Clinical Nutrition*.
 506 2016;103(2):505-511. doi:10.3945/ajcn.115.117689
- Shah SH, Bain JR, Muehlbauer MJ, et al. Association of a peripheral blood metabolic profile with
 coronary artery disease and risk of subsequent cardiovascular events. *Circ Cardiovasc Genet*.
 2010;3(2):207-214. doi:10.1161/CIRCGENETICS.109.852814
- 510 27. Bloomgarden Z. Diabetes and branched-chain amino acids: What is the link? *J Diabetes*.
 511 2018;10(5):350-352. doi:10.1111/1753-0407.12645
- 512 28. Newgard CB, An J, Bain JR, et al. A branched-chain amino acid-related metabolic signature that
 513 differentiates obese and lean humans and contributes to insulin resistance. *Cell Metab.*514 2009;9(4):311-326. doi:10.1016/J.CMET.2009.02.002
- 515 29. Floegel A, Stefan N, Yu Z, et al. Identification of serum metabolites associated with risk of type 2
 516 diabetes using a targeted metabolomic approach. *Diabetes*. 2013;62(2):639-648.
- 517 30. Shalaurova I, Connelly MA, Garvey WT, Otvos JD. Lipoprotein insulin resistance index: a
 518 lipoprotein particle-derived measure of insulin resistance. *Metab Syndr Relat Disord*.
 519 2014;12(8):422-429. doi:10.1089/MET.2014.0050
- 520 31. Flores-Guerrero JL, Gruppen EG, Connelly MA, et al. A newly developed diabetes risk index,
 521 based on lipoprotein subfractions and branched chain amino acids, is associated with incident type
 522 2 diabetes mellitus in the prevend cohort. *J Clin Med.* 2020;9(9):1-17. doi:10.3390/jcm9092781
- 32. Zanetti D, Stell L, Gustafsson S, et al. Plasma proteomic signatures of a direct measure of insulin
 sensitivity in two population cohorts. *Diabetologia*. 2023;66(9):1643-1654. doi:10.1007/s00125023-05946-z
- Wang TJ, Larson MG, Vasan RS, et al. Metabolite profiles and the risk of developing diabetes.
 Nat Med. 2011;17(4):448-453. doi:10.1038/NM.2307

- 34. White PJ, Lapworth AL, McGarrah RW, et al. Muscle-Liver Trafficking of BCAA-Derived
 Nitrogen Underlies Obesity-Related Glycine Depletion. *Cell Rep.* 2020;33(6).
 doi:10.1016/j.celrep.2020.108375
- 531 35. Zhou M, Shao J, Wu CY, et al. Targeting BCAA catabolism to treat obesity-associated insulin
 resistance. *Diabetes*. 2019;68(9):1730-1746. doi:10.2337/db18-0927
- 53336.Lin C, Sun Z, Mei Z, et al. The causal associations of circulating amino acids with blood pressure:534a Mendelian randomization study. *BMC Med.* 2022;20(1). doi:10.1186/s12916-022-02612-w
- 535 37. Biswas D, Duffley L, Pulinilkunnil T. Role of branched-chain amino acid–catabolizing enzymes in intertissue signaling, metabolic remodeling, and energy homeostasis. *FASEB Journal*.
 537 2019;33(8):8711-8731. doi:10.1096/fj.201802842RR
- 538 38. White PJ, McGarrah RW, Herman MA, Bain JR, Shah SH, Newgard CB. Insulin action, type 2
 539 diabetes, and branched-chain amino acids: A two-way street. *Mol Metab.* 2021;52.
 540 doi:10.1016/J.MOLMET.2021.101261
- Jang C, Oh SF, Wada S, et al. A branched-chain amino acid metabolite drives vascular fatty acid
 transport and causes insulin resistance. *Nat Med.* 2016;22(4):421-426. doi:10.1038/nm.4057
- 40. Lynch CJ, Adams SH. Branched-chain amino acids in metabolic signalling and insulin resistance. *Nat Rev Endocrinol.* 2014;10(12):723-736. doi:10.1038/nrendo.2014.171
- 545 41. Timmons JA, Anighoro A, Brogan RJ, et al. A human-based multi-gene signature enables
 546 quantitative drug repurposing for metabolic disease. *Elife*. 2022;11. doi:10.7554/eLife.68832
- 547 42. Soto M, Cai W, Konishi M, Kahn CR. Insulin signaling in the hippocampus and amygdala
 548 regulates metabolism and neurobehavior. *Proc Natl Acad Sci U S A*. 2019;116(13):6379-6384.
 549 doi:10.1073/pnas.1817391116
- 550 43. Chen W, Huang Q, Lazdon EK, et al. Loss of insulin signaling in astrocytes exacerbates
 551 Alzheimer-like phenotypes in a 5xFAD mouse model. *Proceedings of the National Academy of*552 *Sciences*. 2023;120(21):e2220684120. doi:10.1073/PNAS.2220684120
- Mutch DM, Temanni MR, Henegar C, et al. Adipose gene expression prior to weight loss can differentiate and weakly predict dietary responders. *PLoS One*. 2007;2(12).
 doi:10.1371/journal.pone.0001344
- 556 45. Newton RL, Johnson WD, Larrivee S, et al. A Randomized Community-based Exercise Training
 557 Trial in African American Men: Aerobic Plus Resistance Training and Insulin Sensitivity in
 558 African American Men. *Med Sci Sports Exerc*. 2020;52(2):408-416.
 559 doi:10.1249/MSS.00000000002149
- Glynn EL, Piner LW, Huffman KM, et al. Impact of combined resistance and aerobic exercise
 training on branched-chain amino acid turnover, glycine metabolism and insulin sensitivity in
 overweight humans. *Diabetologia*. 2015;58(10):2324-2335. doi:10.1007/s00125-015-3705-6
- 47. Lee S, Gulseth HL, Langleite TM, et al. Branched-chain amino acid metabolism, insulin
 sensitivity and liver fat response to exercise training in sedentary dysglycaemic and
 normoglycaemic men. *Diabetologia*. 2021;64(2):410-423. doi:10.1007/s00125-020-05296-0
- 566 48. Dimenna FJ, Arad AD. The acute vs. chronic effect of exercise on insulin sensitivity: nothing lasts
 567 forever. *Cardiovasc Endocrinol Metab.* 2021;10(3):149-161.
 568 doi:10.1097/XCE.0000000000239

- 569 49. Zheng C, Liu Z. Vascular function, insulin action, and exercise: an intricate interplay. *Trends* 570 *Endocrinol Metab.* 2015;26(6):297-304. doi:10.1016/J.TEM.2015.02.002
- 571 50. King DS, Baldus PJ, Sharp RL, Kesl LD, Feltmeyer TL, Riddle MS. Time course for exercise572 induced alterations in insulin action and glucose tolerance in middle-aged people. *J Appl Physiol*573 (1985). 1995;78(1):17-22. doi:10.1152/JAPPL.1995.78.1.17
- 574 51. Slentz CA, Bateman LA, Willis LH, et al. Effects of exercise training alone vs a combined
 575 exercise and nutritional lifestyle intervention on glucose homeostasis in prediabetic individuals: a
 576 randomised controlled trial. *Diabetologia*. 2016;59(10):2088-2098. doi:10.1007/s00125-016-4051577 z
- 578 52. Slentz CA, Bateman LA, Willis LH, et al. Effects of aerobic vs. resistance training on visceral and
 579 liver fat stores, liver enzymes, and insulin resistance by HOMA in overweight adults from
 580 STRRIDE AT/RT. *Am J Physiol Endocrinol Metab.* 2011;301(5):1033-1039.
 581 doi:10.1152/ajpendo.00291.2011
- 582 53. An P, Teran-Garcia M, Rice T, et al. Genome-wide linkage scans for prediabetes phenotypes in
 583 response to 20 weeks of endurance exercise training in non-diabetic whites and blacks: The
 584 HERITAGE Family Study. *Diabetologia*. 2005;48(6):1142-1149. doi:10.1007/s00125-005-1769-4
- 585 54. Bouchard C, Rankinen T, Timmons JA. Genomics and genetics in the biology of adaptation to exercise. *Compr Physiol.* 2011;1(3):1603-1648. doi:10.1002/cphy.c100059
- 587 55. Phillips BE, Kelly BM, Lilja M, et al. A practical and time-efficient high-intensity interval training
 588 program modifies cardio-metabolic risk factors in adults with risk factors for type II diabetes.
 589 *Front Endocrinol (Lausanne)*. 2017;8(SEP). doi:10.3389/fendo.2017.00229
- 56. Marott SCW, Nordestgaard BG, Tybjaerg-Hansen A, Benn M. Causal associations in type 2
 diabetes development. *Journal of Clinical Endocrinology and Metabolism*. 2019;104(4):13131324. doi:10.1210/jc.2018-01648
- 593 57. Pavone F, Piironen J, Bürkner PC, Vehtari A. Using reference models in variable selection.
 594 Comput Stat. 2023;38(1):349-371. doi:10.1007/s00180-022-01231-6
- 595 58. Piironen J, Paasiniemi M, Vehtari A. Projective inference in high-dimensional problems:
 596 Prediction and feature selection. *Electron J Stat.* 2020;14(1):2155-2197. doi:10.1214/20-EJS1711
- 597 59. *IDF Strategic Plan.*; 2023.
- Keller P, Vollaard NBJ, Gustafsson T, et al. A transcriptional map of the impact of endurance
 exercise training on skeletal muscle phenotype. *J Appl Physiol*. 2011;110(1):46-59.
 doi:10.1152/japplphysiol.00634.2010
- 601 61. Manning AK, Hivert MF, Scott RA, et al. A genome-wide approach accounting for body mass
 602 index identifies genetic variants influencing fasting glycemic traits and insulin resistance. *Nat* 603 *Genet.* 2012;44(6):659-669. doi:10.1038/ng.2274
- 604 62. Crossland H, Smith K, Idris I, Phillips BE, Atherton PJ, Wilkinson DJ. Exploring mechanistic
 605 links between extracellular branched-chain amino acids and muscle insulin resistance: an in vitro
 606 approach. *Am J Physiol Cell Physiol*. 2020;319(6):C1151-C1157.
 607 doi:10.1152/AJPCELL.00377.2020
- 608 63. Roth Flach RJ, Bollinger E, Reyes AR, et al. Small molecule branched-chain ketoacid
 609 dehydrogenase kinase (BDK) inhibitors with opposing effects on BDK protein levels. *Nat*610 *Commun.* 2023;14(1). doi:10.1038/S41467-023-40536-Y

- 611 64. Sitryawan A, Hawes JW, Harris RA, Shimomura Y, Jenkins AE, Hutson SM. A molecular model
 612 of human branched-chain amino acid metabolism. *Am J Clin Nutr.* 1998;68(1):72-81.
 613 doi:10.1093/AJCN/68.1.72
- 614 65. Shin AC, Fasshauer M, Filatova N, et al. Brain Insulin Lowers Circulating BCAA Levels by
 615 Inducing Hepatic BCAA Catabolism. *Cell Metab.* 2014;20(5):898-909.
 616 doi:10.1016/J.CMET.2014.09.003
- 66. Sayda MH, Abdul Aziz MH, Gharahdaghi N, et al. Caloric restriction improves glycaemic control
 without reducing plasma branched-chain amino acids or keto-acids in obese men. *Sci Rep.*2022;12(1). doi:10.1038/S41598-022-21814-Z
- 620 67. Pavone F, Piironen J, Bürkner PC, Vehtari A. Using reference models in variable selection.
 621 *Comput Stat.* 2023;38(1):349-371. doi:10.1007/S00180-022-01231-6/FIGURES/9
- 622 68. Piironen J, Paasiniemi M, Vehtari A. Projective inference in high-dimensional problems:
 623 Prediction and feature selection. *https://doi.org/101214/20-EJS1711*. 2020;14(1):2155-2197.
 624 doi:10.1214/20-EJS1711
- 625 69. Tripathy D, Cobb JE, Gall W, et al. A novel insulin resistance index to monitor changes in insulin
 626 sensitivity and glucose tolerance: The ACT NOW study. *Journal of Clinical Endocrinology and*627 *Metabolism.* 2015;100(5):1855-1862. doi:10.1210/jc.2014-3824
- Wallace TM, Levy JC, Matthews DR, Homa T. Use and Abuse of HOMA Modeling. *Diabetes Care*. 2004;27(6):1487-1495.
- 630 71. Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA)
 631 evaluation uses the computer program. *Diabetes Care*. 1998;21(12):2191-2192.
 632 doi:10.2337/DIACARE.21.12.2191
- 633 72. Matsuda M, Defronzo RA. Insulin Sensitivity Indices Obtained From Comparison with the euglycemic insulin clamp. *Diabetes Care*. 1999;22(9):1462-1470.
- 635 73. Utzschneider KM, Prigeon RL, Faulenbach M V., et al. Oral Disposition index predicts the
 636 development of future diabetes above and beyond fasting and 2-h glucose levels. *Diabetes Care*.
 637 2009;32(2):335-341. doi:10.2337/dc08-1478
- 638 74. Marott SCW, Nordestgaard BG, Tybjaerg-Hansen A, Benn M. Causal associations in type 2
 639 diabetes development. *Journal of Clinical Endocrinology and Metabolism*. 2019;104(4):1313640 1324. doi:10.1210/jc.2018-01648
- 641 75. Hagströmer M, Oja P, Sjöström M. The International Physical Activity Questionnaire (IPAQ): a
 642 study of concurrent and construct validity. *Public Health Nutr*. 2006;9(6):755-762.
- 643 76. Godel H, Graser T, Földi P, Pfaender P, Fürst P. Measurement of free amino acids in human
 644 biological fluids by high-performance liquid chromatography. *J Chromatogr A*. 1984;297:49-61.
 645 doi:https://doi.org/10.1016/S0021-9673(01)89028-2
- Vesali RF, Klaude M, Rooyackers O, Wernerman J. Amino acid metabolism in leg muscle after an
 endotoxin injection in healthy volunteers. *Am J Physiol Endocrinol Metab.* 2005;288:360-364.
 doi:10.1152/ajpendo.00248.2004.-Decreased
- 649 78. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic
 650 resonance spectroscopy. *Clin Lab Med.* 2006;26(4):847-870. doi:10.1016/J.CLL.2006.07.006

- 79. Wolak-Dinsmore J, Gruppen EG, Shalaurova I, et al. A novel NMR-based assay to measure
 circulating concentrations of branched-chain amino acids: Elevation in subjects with type 2
 diabetes mellitus and association with carotid intima media thickness. *Clin Biochem.* 2018;54:9299. doi:10.1016/J.CLINBIOCHEM.2018.02.001
- 80. Bürkner PC. brms: An R package for Bayesian multilevel models using Stan. J Stat Softw.
 2017;80. doi:10.18637/jss.v080.i01

657

659 **Table 1.**

	Μ	IP		S2		S-PD	
	Pre	Post	Pre	Post	Pre	Post	
Ν	179	109	116	85	149	122	
Gender (f:m)	100:79	58:51	58:58	43:41	89:60	71:51	
Age	38 (18)	38 (18)	50 (14.5)	50 (17)	59 (11)	59 (12)	
Weight (kg)	91.5 (20.1)	91.6 (21)	88 (17.5)	85.5 (13.2)	86.2 (17.4)	83.7 (16.5)	
BMI	31 (5.5)	30.6 (4.766)	30.4 (4.88)	30 (5)	30.2 (4.45)	29.4 (4.6)	
SBP (mmHg)	125 (14)	121 (16)	119 (16)	121 (18)	126 (16)	122 (21)	
DPB (mmHg)	78 (13)	77 (14)	80 (14)	80 (14)	75 (12)	72 (13)	
MAP (mmHg)	94 (13)	90 (12)	93 (15)	80 (14)	91 (13)	89 (13)	
Resting HR	70 (12)	68 (12)	74 (16)	NA	NA	NA	
VO2 max (mL/min/kg)	27.5 (10)	30.2 (11)	26.7 (7.56)	30.7 (9.6)	23.8 (7.05)	26 (8.25)	
Fasting glucose (mmol/L)	4.61 (0.43)	4.6 (0.4)	5.26 (0.65)	5.33 (0.77)	5.78 (0.78)	5.81 (0.74)	
2-hour glucose (mmol/L)	6.67 (1.51)	6.32 (1.9)	NA	NA	7.66 (3.43)	7.22 (2.3)	
Fasting insulin (imm)	84.4 (65.4)	78.7 (51.7)	55.7 (43.7)	44.3 (33.5)	236 (234)	195 (199)	
Fasting insulin (ELISA)	57.7 (42.5)	50.9 (37.6)	30.7 (43.7)	36.6 (33.2)	49.6 (58.4)	40.3 (47.2)	
HOMA2 IR	1.2 (0.9)	1.07 (0.8)	1.07 (1)	0.81 (0.71)	1.12 (1.3)	0.95 (1.07)	
Sum BCAA (µmol/L)	424 (133)	438 (139)	424 (90.4)	465 (85.5)	439 (99.1)	429 (96.1)	
Leucine (µmol/l)	120 (40.6)	126 (39)	153 (36.2)	171.7 (39.5)	148 (37.9)	148 (35.1)	
Isoleucine (µmol/L)	62.89 (22.6)	63.8 (21.7)	66.8 (20.1)	65.6 (22.5)	62.8 (19.7)	59.8 (14.5)	
Valine (µmol/l)	239 (70.2)	247 (75.5)	208 (51.8)	230 (50)	221 (50.2)	220 (49.5)	
HDL (mmol/L)	1.02 (0.39)	1.04 (0.4)	0.9 (0.33)	1.12 (0.33)	1.06 (0.39)	1.11 (0.37)	
LDL (mmol/L)	2.64 (0.99)	2.5 (0.96)	2.45 (0.87)	2.72 (0.75)	3.12 (0.96)	2.96 (0.82)	
TAG (mmol/L)	1.17 (0.75)	1.09 (0.72)	1.4 (0.85)	1.25 (0.78)	1.3 (0.83)	1.18 (0.95)	
ALA (µmol/L)	321 (107)	326 (127)	419 (110)	405 (150)	399 (98)	390 (123)	

660

661

Table 1. Demographics. Median and IQR. All available samples were utilised for baseline
 modelling. In each analysis, only subjects with complete data were used in the pre/post

664 modelling, resulting in $\sim 20\%$ fewer subjects than recruited or completing the intervention.

Table 2.

Cohort	Model	RMSE	MAE	r ²	Adj r ²	p value	
	1	0.208	0.167	0.272	0.255	< 0.001	
MP	2	0.205	0.164	0.302	0.282	< 0.001	
n=179	3	0.208	0.161	0.309	0.281	< 0.001	
	4	0.206	0.161	0.327	0.295	< 0.001	
	1	0.267	0.215	0.265	0.238	< 0.001	
S-2	2	0.271	0.221	0.298	0.266	< 0.001	
n=116	3	0.255	0.208	0.366	0.325	< 0.001	
	4	0.254	0.208	0.389	0.343	< 0.001	
	1	0.295	0.237	0.202	0.18	< 0.001	
S-PD	2	0.281	0.227	0.265	0.239	< 0.001	
n=149	3	0.293	0.229	0.304	0.269	< 0.001	
	4	0.291	0.223	0.339	0.301	< 0.001	
Model $1 = age+gender+log_{10}BMI+fasting glucose$							
Model $2 = model 1 + sumBCAA$							
Model $3 = model 1 + HDL + LDL + TAG$							
Model $4 = mode$	el 1 + HDL-	+LDL+TAG	+sumBCAA	L			

Table 2. K-fold cross validation multiple linear regression predicting baseline log₁₀ fasting insulin from
 clinical and metabolomic variables.



Figure 1. Insulin assay statistical performance for identifying differences in pre vs post exercise
 training samples (MP cohort). Fasting insulin (pmol/L) was measured using a high sensitivity

675 ELISA (left) and the Immulite 2000 automated analyser (right). P-values are calculated from

676 paired t-tests on log10 fasting insulin (pmol/L). Only the ELISA could detect a significant

- 677 treatment effect.
- 678

672



Figure 2. Scatter plots with OLS line of best fit (95% CI shaded) between log10 fasting insulin
and clinical and metabolic variables. A) MP, B) S-2 and C) S-PD





686 Figure 3. Utility of baseline clinical and metabolomic variables to classify HOMA2-IR status at

- 687 1.3 unit threshold reflecting the analysis of Marott et al. K-fold cross validation logistic
- 688 regression ROC curves for A. MP, B. S-2 and C. S-PD.



689 690

Figure 4. Scatter plots with OLS line of best fit (95% CI shaded) between delta fasting insulin
and clinical and metabolic variables. A) MP, B) S-2 and C) S-PD



694

Figure 5. Left panel; Posterior predictive distributions for A. MP, B. S-2 and C. S-PD. Right

696 panel; Expected log predictive density (Elpd, upper trace) and root mean square error (RMSE,
697 lower trace) for D. MP, E. S-2 and F. S-PD. Elpd and RMSE are shown with 95% nominal
608 conservation intervalue

698 coverage intervals.

Table S1. Linear regression modelling using log10 fasting insulin as dependent variable. Note the sample sizes reflecting all subjects
 with data for each individual clinical parameter or metabolomic measure. In final integrated modelling only subjects with all

with data for each individual clinical parameter or metabolomic measure. In final integrated modelling only subjects with all
 completes values were included.

META-PREDICT								
Model	n	Intercept p	Intercept estimate	Estimates	95% CI	р	Adj r ²	
Age	188	< 0.0001	1.8737	-0.0032	-0.0069 - 0.0005	0.0918	0.010	
Gender	186	< 0.0001	1.8254	-0.1227	-0.19280.0527	0.0007	0.056	
BMI (log10)	188	0.5690	-0.2714	1.3532	0.7283 - 1.9781	<0.0001	0.084	
SBP	175	< 0.0001	1.1684	0.0048	0.0016 - 0.0080	0.0038	0.042	
DBP	174	< 0.0001	1.2888	0.0060	0.0020 - 0.0099	0.0030	0.044	
MAP	174	< 0.0001	1.1370	0.0066	0.0026 - 0.0106	0.0013	0.053	
Fasting glucose	188	0.1037	-51.5267	25.7240	12.2694 - 39.1787	0.0002	0.066	
HDL	185	< 0.0001	2.0214	-0.2481	-0.36040.1358	<0.0001	0.089	
LDL	184	< 0.0001	1.5896	0.0599	0.0157 - 0.1041	0.0082	0.032	
Triglycerides	187	< 0.0001	1.6140	0.1110	0.0615 - 0.1604	<0.0001	0.091	
Sum of BCAA	184	< 0.0001	1.3981	0.0008	0.0005 - 0.0011	<0.0001	0.123	
Isoleucine	184	< 0.0001	1.4579	0.0045	0.0027 - 0.0063	<0.0001	0.115	
Leucine	184	< 0.0001	1.4408	0.0025	0.0015 - 0.0036	<0.0001	0.106	
Valine	184	< 0.0001	1.3818	0.0015	0.0009 - 0.0021	<0.0001	0.126	

Alanine	184	< 0.0001	1.5930	0.0005	0.0001 - 0.0009	0.0148	0.027	
STRRIDE-2								
Model	n	Intercept p	Intercept estimate	Estimates	95% CI	р	Adj r ²	
Age	128	< 0.0001	1.7792	-0.0027	-0.0082 - 0.0027	0.3227	0	
Gender	128	< 0.0001	1.7628	-0.0886	-0.2063 - 0.0290	0.1386	0.009	
BMI (log10)	128	0.0024	-2.8007	3.0012	1.7913 - 4.2110	<0.0001	0.154	
SBP	111	< 0.0001	1.2972	0.0029	-0.0017 - 0.0076	0.2139	0.005	
DBP	111	0.0001	1.1314	0.0066	-0.0004 - 0.0136	0.0650	0.022	
МАР	111	0.0002	1.1428	0.0055	-0.0009 - 0.0119	0.0911	0.017	
Fasting glucose	118	0.0001	0.9260	0.1394	0.0582 - 0.2206	0.0009	0.083	
HDL	128	<0.0001	1.8172	-0.2448	-0.42080.0687	0.0068	0.049	
LDL	128	<0.0001	1.8172	-0.0606	-0.1486 - 0.0274	0.1753	0.007	
Triglycerides	128	<0.0001	1.4320	0.1329	0.0677 - 0.1981	0.0001	0.107	
Sum of BCAA	126	<0.0001	0.8578	0.0017	0.0009 - 0.0024	0.0001	0.117	
Isoleucine	126	<0.0001	1.2102	0.0066	0.0029 - 0.0102	0.0005	0.085	
Leucine	126	<0.0001	1.1699	0.0027	0.0008 - 0.0047	0.0064	0.051	
Valine	126	<0.0001	0.8261	0.0035	0.0019 - 0.0050	<0.0001	0.13	
Alanine	128	<0.0001	1.2359	0.0010	0.0003 - 0.0016	0.0027	0.062	

STRRIDE PD							
Model	n	Intercept p	Intercept estimate	Estimates	95% CI	р	Adj r ²
Age	155	< 0.0001	1.9753	-0.0046	-0.0116 - 0.0024	0.1944	0.005
Gender	155	< 0.0001	1.7253	-0.0395	-0.1455 - 0.0665	0.463	0
BMI (log10)	155	0.1983	-1.2123	1.9683	0.7168 - 3.2198	0.0023	0.053
SBP	134	< 0.0001	1.2980	0.0032	-0.0009 - 0.0074	0.1260	0.010
DPB	134	< 0.0001	1.4408	0.0035	-0.0025 - 0.0096	0.2507	0.002
МАР	134	< 0.0001	1.2897	0.0045	-0.0014 - 0.0105	0.1365	0.009
Fasting glucose	154	0.2343	0.3187	0.2357	0.1464 - 0.3251	<0.0001	0.146
HDL	153	< 0.0001	2.0821	-0.3326	-0.46020.2051	<0.0001	0.144
LDL	151	< 0.0001	1.5234	0.0568	-0.0180 - 0.1316	0.1355	0.008
Triglycerides	153	< 0.0001	1.5573	0.0961	0.0311 - 0.1610	0.0040	0.047
Sum of BCAA	155	< 0.0001	1.1048	0.0014	0.0007 - 0.0021	0.0001	0.091
Isoleucine	155	< 0.0001	1.2519	0.0071	0.0038 - 0.0104	<0.0001	0.098
Leucine	155	< 0.0001	1.3715	0.0022	0.0004 - 0.0041	0.0159	0.031
Valine	155	< 0.0001	0.9665	0.0033	0.0021 - 0.0046	<0.0001	0.147
Alanine	155	<0.0001	1.4536	0.0006	-0.0000 - 0.0013	0.0675	0.015

Table S2 - K-fold cross validation logistic regression model statistics for combined model predicting insulin resistance (HOMA2 IR706 ≥ 1.3) using age, BMI, gender, sum of branched chain amino acids, HDL, LDL and triglycerides.707

	МР	S2	S-PD
Accuracy (95% CI)	0.676 (0.602-0.744)	0.707 (0.615-0.788)	0.644 (0.562-0.721)
Kappa	0.339	0.347	0.27
Sensitivity	0.58	0.512	0.563
Specificity	0.755	0.822	0.706
PPV	0.662	0.629	0.59
NPV	0.685	0.741	0.682
Prevalence	0.453	0.371	0.43
Detection rate	0.263	0.19	0.242





- standard), B) (ELISA using titration international insulin standard), and C) Immulite vs ELISA
- standard curve values using international insulin standard once converted to uIU/ml)





- 2000 assays.



- 719 **Figure S3.** Correlation plots showing strength of correlation between the variables used in the
- 720 generation of linear models to predict change in circulating insulin across lifestyle interventions.
- 721 A. MP, B. S-2 and C. S-PD.



724 Figure S4. Hierarchical clustering of subjects by their metabolomic profile demonstrating that

there is no centre specific bias.



Figure S5-6. S5) S-2 HDL assay performance. A) Comparison of mass spectroscopy and nuclear magnetic resonance (NMR) measurement of HDL using linear regression. B) Bland-Altman plot to estimate of bias with 95% confidence interval shown in blue, with upper (green) and lower (red) limits. S6). S-2 TAG assay performance. A) Comparison of mass spectroscopy and nuclear magnetic resonance (NMR) measurement of TAG using linear regression. B) Bland-Altman plot to estimate of bias with 95% confidence interval shown in blue, with upper (green) and lower (red) limits. S6). S-2 TAG assay performance. A) Comparison of mass spectroscopy and nuclear magnetic resonance (NMR) measurement of TAG using linear regression. B) Bland-Altman plot to estimate of bias with 95% confidence interval shown in blue, with upper (green) and lower (red) limits.



737 Test spec TAG (mmol/)
738 Figure S7-8. S7) S-PD HDL assay performance. A) Comparison of mass spectroscopy and
739 nuclear magnetic resonance (NMR) measurement of HDL using linear regression. B) Bland740 Altman plot to estimate of bias with 95% confidence interval shown in blue, with upper (green)
741 and lower (red) limits. S8). S-PD TAG assay performance. A) Comparison of mass spectroscopy
742 and nuclear magnetic resonance (NMR) measurement of TAG using linear regression. B) Bland743 Altman plot to estimate of bias with 95% confidence interval shown in blue, with upper (green)
744 and lower (red) limits.